Short Interest in AngioDynamics, Inc. (NASDAQ:ANGO) Grows By 78.6%

AngioDynamics, Inc. (NASDAQ:ANGO) was the recipient of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 1,470,000 shares, an increase of 78.6% from the January 15th total of 822,900 shares. Based on an average trading volume of 677,900 shares, the days-to-cover ratio is presently 2.2 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright upped their price objective on shares of AngioDynamics from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Friday, January 10th.

AngioDynamics Price Performance

Shares of ANGO stock opened at $10.45 on Thursday. The firm has a 50 day moving average of $10.36 and a two-hundred day moving average of $8.29. AngioDynamics has a 52 week low of $5.26 and a 52 week high of $13.50.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.07. The business had revenue of $72.90 million during the quarter, compared to analysts’ expectations of $70.93 million. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The company’s revenue for the quarter was down .1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.05) EPS. As a group, analysts anticipate that AngioDynamics will post -0.37 EPS for the current year.

Insider Transactions at AngioDynamics

In other news, SVP Warren Nighan, Jr. sold 4,060 shares of the company’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total value of $49,978.60. Following the transaction, the senior vice president now directly owns 41,817 shares in the company, valued at approximately $514,767.27. This represents a 8.85 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On AngioDynamics

Several institutional investors have recently modified their holdings of ANGO. SBI Securities Co. Ltd. purchased a new stake in shares of AngioDynamics during the 4th quarter worth $28,000. R Squared Ltd acquired a new stake in AngioDynamics during the 4th quarter worth $49,000. US Bancorp DE raised its stake in AngioDynamics by 1,938.0% during the 4th quarter. US Bancorp DE now owns 6,705 shares of the medical instruments supplier’s stock worth $61,000 after acquiring an additional 6,376 shares in the last quarter. Quarry LP raised its stake in AngioDynamics by 40.9% during the 3rd quarter. Quarry LP now owns 8,518 shares of the medical instruments supplier’s stock worth $66,000 after acquiring an additional 2,471 shares in the last quarter. Finally, CWM LLC raised its stake in AngioDynamics by 981.3% during the 3rd quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier’s stock worth $76,000 after acquiring an additional 8,832 shares in the last quarter. 89.43% of the stock is owned by hedge funds and other institutional investors.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.